The American Journal of Managed Care

Despite Uptake Barriers, Real-World Biosimilar Data Demonstrate Safety, Efficacy, Cost-Effectiveness

Presenters explored the real-world evidence in support of biosimilars at the Academy of Managed Care Pharmacy 2024 annual meeting. Biosimilars were a recurring subject at the Academy of Managed Care ...
The Motley Fool

What Is a Biosimilar? Overview and Example

Biosimilars provide cheaper alternatives to biologics, potentially reducing profitability for original drug makers. Long-lasting drug patents (up to 40.5 years) support sustained revenue for ...
The American Journal of Managed Care

Overview of Biosimilars for Immune-Mediated Inflammatory Diseases: Summary of Current Evidence

Biosimilars offer the potential to deliver substantial cost savings in biologic therapy and to contribute to increased patient access to biologic treatments, both of which are particularly relevant ...
Forbes

Biosimilars Are Making Inroads In U.S., But It’s Still A Bumpy Ride

Forbes contributors publish independent expert analyses and insights. Joshua Cohen is a Boston-based writer who covers health policy. Biosimilars offer clinically effective treatment alternatives to ...

Rand Paul's biosimilar drug bill could cut costs, speed patient access

Sen. Rand Paul's (R–Ky.) proposed Expedited Access to Biosimilars Act was unanimously voted out of the Senate Health, ...
JD Supra

Introduction to Biologics and Biosimilars

Biologics are a fast-growing class of therapeutic compounds. In the United States, patent litigation between biologic manufacturers and biosimilar applicants occurs under the Biologics Price ...
RAPS

Regulatory Explainer: Everything You Need to Know About Biosimilars

For more than a decade now, biotech and pharmaceutical companies have brought a new class of treatments – biosimilars – to markets around the world (from the EU to India to South Korea to the US), ...
The Business Journals

An action plan: How employers can use biosimilars to reduce health care costs

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. With nearly half of the U.S. population covered by employer ...
Healthline

FDA Approves Biosimilar That Can Treat Crohn's Disease, Psoriasis

The FDA has approved a new biosimilar drug for inflammatory disease, based on the popular Stelara (ustekinumab). Biosimilar drugs are biologically similar, but not identical to existing biologics. The ...
JD Supra

How Biosimilars Are Approved and Litigated: Patent Dance Timeline

A biosimilar is a biological product that is highly similar to and has no clinically meaningful differences from an FDA-approved reference biological product. Biosimilar applicants have a number of ...
Healio

Norway 'excellent example' of how to increase access to biosimilars

Please provide your email address to receive an email when new articles are posted on . The European Union, and specifically Norway, has demonstrated successful strategies for making biosimilars ...
FiercePharma

FDA finalizes guidance on promotional materials for biologics and biosimilars

A new guidance document issued by the FDA this week offers recommendations for how makers of prescription biosimilars and biologic reference products should approach promotional advertising and ...